Abstract library

12 results for "Tucci".
#2698 Safety and Efficacy of Salvage PRRT with 177Lu-DOTA-Octreotate in Patients with Well-Differentiated Metastatic Neuroendocrine Tumours (NET)
Introduction: Peptide receptor radionuclide therapy (PRRT) is an effective therapy in patients with a somatostatin receptor-positive neuroendocrine tumour (NET). NETTER-1 trial demonstrated high efficacy and low toxicity of four cycles.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Nariman Ghaleb
#2876 Efficacy of Surufatinib in Western Patients (pts) with Pancreatic Neuroendocrine Tumors (PanNETs)
Introduction: Surufatinib is a targeted inhibitor of tyrosine kinases VEGFR1, 2, & 3, FGFR1, and CSF-1R. The safety profile was favorable in 2 completed studies (NCT02133157, NCT02267967) conducted in China. A recent phase 3 placebo controlled study (NCT02588170) confirmed safety, and demonstrated superior efficacy (PFS: 9.2 v 3.8 months) of Surufatinib in Chinese pts with advanced extra-pancreatic NETs (epNET).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Targeted therapies
Presenting Author: Medical Writer Kimberly Louis
Authors: Dasari A, Paulson S, Sung M, Tucci C, ...
#79 PTOV-1 overexpression in neuroendocrine tumors: a new molecular marker
Introduction: PTOV-1 (Prostate Tumor Overexpressed-1) is a novel protein encoded by 12-exon gene localized in chromosome 19q.13.3. Recently identified as an androgen-induced gene, it is involved in prostate cell proliferation and in prostate human cancer. PTOV-1 expression has been demonstrated in neuroendocrine cells of normal prostate tissue. Preliminary data indicate that PTOV-1 can be related to flotilin, integrins and other cellular factors involved in cancer progression.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: MD INES DE TORRES
#350 RAD001 and Octreotide LAR as first-line treatment of well differentiated neuroendocrine tumors: an I.T.M.O. (Italian Trials in Medical Oncology) group study
Introduction: RAD001 has shown antitumor activity in pancreatic neuroendocrine tumors (NETs) and it seems to work synergistically with somatostatine analogues.
Conference:
Category: Basic
Presenting Author: Dr Laura Catena
#383 Everolimus and Octreotide LAR in Neuroendocrine Tumors: An I.T.M.O. (Italian Trials in Medical Oncology) Group Study
Introduction: Everolimus has shown antitumor activity in pancreatic neuroendocrine tumors (NETs) and it seems to work synergistically with octreotide.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Emilio Bajetta
#569 Lack of Accuracy of Circulating Chromogranin A in the Preoperative Diagnosis of Lung Neuroendocrine Tumors
Introduction: While the role of the circulating neuroendocrine (NE) marker Chromogranin A (CgA) in the clinical management of GEP NET has been extensively discussed, the same role in thoracic NE tumors (TNET) remains to be better clarified.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Piero Ferolla
#859 Pancreatic Neuroendocrine Tumors (PNETs): Role of Endoscopic UltraSound-Fine Needle Aspiration (EUS-FNA) and Accuracy of Ki-67 Measurement on Cytological Specimens
Introduction: The role of EUS-FNA in preoperative diagnosis and grading of pNETs is well-established, but it is unclear how Ki-67 expression on cytological specimens obtained by EUS-FNA reflects the value found on surgical specimens.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Pathology, grading, staging
Presenting Author: Claudio G De Angelis
#908 Role of Epithelial-to-Mesenchymal Transition Markers in Predicting Bone and Visceral Metastases from NETs
Introduction: Epithelial-to-mesenchymal transition (EMT) of tumor cells has been recently postulated as a pivotal mechanism driving metastatic spread.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Biomarkers
Presenting Author: Valeria Simone
Keywords: EMT, biomarker
#1139 Role of Enteroclysis MDTC in the Diagnosis and Follow-Up of Ileal Neuroendocrine Tumors
Introduction: Among all the well differentiated neuroendocrine tumors (NET) those originating from ileum present the more relevant diagnostic difficulties and remain therefore occult in a relevant percentage of cases in all the stages
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: MD Daniele Maiettini
#1344 Reassessment of Proliferative Activity at Disease Progression in Neuroendocrine Neoplasms
Introduction: Ki67 is a key factor influencing prognosis and treatment in NENs. However, whether repeating histology at time of progression of disease (PD) is debated
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Pathology, grading, staging
Presenting Author: Dr. Francesco Panzuto